AFMD

Affimed N V

Healthcare Biotechnology NASDAQ

About the company

Affimed NV is an innovative clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through the discovery and development of targeted cancer immunotherapies. With a strong emphasis on immuno-oncology, Affimed aims to leverage the power of the body's immune system to effectively combat tumor cells. At the forefront of its research and development efforts, Affimed has an exciting pipeline of product candidates. These candidates offer promising prospects in treating various types of cancer by modulating the patient's immune responses. By identifying and targeting specific immune checkpoints and activating the body's natural defense mechanisms, Affimed's therapies hold the potential to deliver highly precise and effective treatments. The company's commitment to advancing the field of immuno-oncology extends beyond single therapies. Affimed is actively exploring the potential of combination therapies, recognizing that the greatest impact can often be achieved through synergistic approaches. By combining different therapeutic approaches, Affimed aims to enhance treatment outcomes and improve patient responses. Focusing on global impact, Affimed derives a significant portion of its revenue from the United States, reflecting its business presence and partnerships in this key market. Additionally, Affimed has a notable presence in Europe, particularly in Germany, where it continues to strengthen its research and development capabilities. With a team of dedicated scientists and researchers, Affimed continues to push the boundaries of cancer treatment. Through rigorous scientific exploration and advancing technological capabilities, the company is committed to delivering safe and effective therapies to patients in need. By understanding the complexity of the immune system and its relationship with cancer, Affimed is paving the way for a future where cancer can be treated more effectively. In conclusion, Affimed NV is a pioneering biopharmaceutical company that is actively contributing to the field of immuno-oncology. By harnessing the body's immune defenses and developing targeted therapies, Affimed aims to transform cancer treatment and improve patient outcomes. With a strong global presence and an unwavering commitment to scientific excellence, Affimed is poised to make significant contributions to the advancement of cancer immunotherapy.

Website: https://www.affimed.com

Data updated: June 2, 2026

Sector comparison

We compare this company with the typical (middle) company in the same industry to show how it looks against similar businesses. This is information, not a recommendation.

Healthcare · 1345 peers in sector

Metric AFMD Sector median Vs. industry
P/E - 20.13
EPS -5.09 USD -1.14 USD ↓ Below average
Dividend yield 0.00% 0.00%
Profit margin 0.00% 0.00%
ROE -1.49% -58.89% ↓ Below average

Higher and lower here are only a comparison with the typical company in the industry — a higher or lower value on its own does not mean better or worse.

Financial statements & historical data

Income statements, balance sheets, cash flow, earnings and dividend history are available for registered users

Sign up for free

AI Summary

AI-generated company analysis is available for registered users.

Sign up for free

Where does this data come from?

Frequently Asked Questions

What is Affimed N V?
Affimed NV is an innovative clinical-stage biopharmaceutical company dedicated to revolutionizing cancer treatment through the discovery and development of targeted cancer immunotherapies. With a strong emphasis on immuno-oncology, Affimed aims to leverage the power of the body's immune system to effectively combat tumor cells. At the forefront of its research and development efforts, Affimed has an exciting pipeline of product candidates. These candidates offer promising prospects in treating various types of cancer by modulating the patient's immune responses. By identifying and targeting specific immune checkpoints and activating the body's natural defense mechanisms, Affimed's therapies hold the potential to deliver highly precise and effective treatments. The company's commitment to advancing the field of immuno-oncology extends beyond single therapies. Affimed is actively exploring the potential of combination therapies, recognizing that the greatest impact can often be achieved through synergistic approaches. By combining different therapeutic approaches, Affimed aims to enhance treatment outcomes and improve patient responses. Focusing on global impact, Affimed derives a significant portion of its revenue from the United States, reflecting its business presence and partnerships in this key market. Additionally, Affimed has a notable presence in Europe, particularly in Germany, where it continues to strengthen its research and development capabilities. With a team of dedicated scientists and researchers, Affimed continues to push the boundaries of cancer treatment. Through rigorous scientific exploration and advancing technological capabilities, the company is committed to delivering safe and effective therapies to patients in need. By understanding the complexity of the immune system and its relationship with cancer, Affimed is paving the way for a future where cancer can be treated more effectively. In conclusion, Affimed NV is a pioneering biopharmaceutical company that is actively contributing to the field of immuno-oncology. By harnessing the body's immune defenses and developing targeted therapies, Affimed aims to transform cancer treatment and improve patient outcomes. With a strong global presence and an unwavering commitment to scientific excellence, Affimed is poised to make significant contributions to the advancement of cancer immunotherapy.
How big is Affimed N V?
The market capitalization of Affimed N V — the combined value of all its shares — is 3.0 M USD. The higher the market cap, the larger the company. (as of 2026-06-02)
Does Affimed N V pay dividends?
The dividend yield of Affimed N V is 0.00% — it shows the annual dividend relative to the share price. This is information, not a recommendation. (as of 2026-06-02)
What sector does Affimed N V belong to?
Affimed N V operates in the Healthcare sector, industry: Biotechnology.

What do you gain?

With Ecrumen you gain full control over your investments and assets!

All your assets
Stock market investments, real estate, bonds. Be aware of what you have in your portfolio!
AI at the service of your investments
Analyze and optimize your investments using the latest technologies. Sentiments, analyses, tips, reports. Always with up-to-date data!
A community eager to help
Find a place with people similar to you. Share your opinions, see how others manage their investments. Get help with the problems that bother you!
What do you gain?

Want to stay up to date?

Subscribe to our newsletter to stay up to date with Ecrumena news and market information. No spam, unsubscribe in one click.

For more information, please refer to our terms of use.

0/120